cytochrome c oxidase assembly factor COX20Genealiases: FAM36A · MC4DN11
Q-omics provides the consensus-scored COX20 profile across patient tissues and cancer cell-line models. COX20 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, COX20 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, COX20 RNA expression shows 20,823 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KICH, and UVM as cancer lineages where COX20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX20 survival associations across molecular data types. COX20 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX20 RNA expression–survival associations across cancer types. High COX20 expression shows unfavorable associations in ACC, UVM, KICH, MESO and CESC, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for COX20 RNA expression.
This table summarizes COX20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for COX20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX20 shows lower tumor expression in KICH, THCA, KIRP and KIRC and higher tumor expression in LIHC and HNSC. The KICH box plot shows higher COX20 RNA expression in normal versus tumor tissue (log2 FC = −1.260, t-test p < 0.001).
This table shows molecular features associated with COX20 in patient tissues and cancer cell lines. In patient samples, COX20 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, COX20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_SCLC.
